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Vitamin D deﬁciency is an increasingly described phenom-
enon worldwide, with well-known impacts on calcium me-
tabolism and bone health. Vitamin D has also been
associated with chronic health problems such as bowel and
colonic cancer, arthritis, diabetes and cardiovascular dis-
ease. In recent decades, there has been increased awareness
of the impact of vitamin D on muscle morphology and
function, but this is not well recognized in the Sports
Medicine literature. In the early 20th century, athletes
and coaches felt that ultraviolet rays had a positive impact
on athletic performance, and increasingly, evidence is accu-
mulating to support this view. Both cross-sectional and
longitudinal studies allude to a functional role for vitamin
DinmuscleandmorerecentlythediscoveryofthevitaminD
receptor in muscle tissue provides a mechanistic under-
standing of the function of vitamin D within muscle. The
identiﬁcation of broad genomic and non-genomic roles for
vitamin D within skeletal muscle has highlighted the poten-
tial impact vitamin D deﬁciency may have on both under-
performance and the risk of injury in athletes. This review
describes the current understanding of the role vitamin D
plays within skeletal muscle tissue.
Vitamin D is a secosteroid produced in the skin, under
the inﬂuence of ultraviolet-B (UVB) radiation con-
verting 7-dehydrocholesterol to pre-vitamin D3.I nt h e
dermis, pre-vitamin D3 is rapidly converted to vitamin
D3 (cholecalciferol), before its subsequent conversion
to 25-hydroxy vitamin D (25(OH)D) in the liver.
Further hydroxylation of 25-hydroxy vitamin D to
its active form, 1,25 hydroxy vitamin D (1,25(OH)2D),
occurs in the kidney (Holick, 2007). Lesser quantities
are also found in the diet in the form of vitamin D2
(ergocalciferol), which undergoes the same hydroxy-
lation process. Vitamin D is transported in the blood,
bound to vitamin D binding protein.
Vitamin D is well recognized for its role in calcium
and phosphorus homeostasis. In conjunction with
parathyroid hormone (PTH), vitamin D plays a
critical role in calcium homeostasis (Cashman,
2007), and as a result, vitamin D deﬁciency has
been implicated in osteoporotic and stress-related
fractures (Ruohola et al., 2006; Lappe et al., 2007,
2008). Less well recognized are its genomic and non-
genomic roles in other tissues (Holick, 2006), despite
cross-sectional data linking vitamin D deﬁciency to
bowel and colonic cancer, arthritis, diabetes and
cardiovascular disease (Pani et al., 2000; Hypponen
et al., 2001, 2008; Dietrich et al., 2004; Holick, 2004,
2006, 2007; Garland et al., 2006; Giovannucci et al.,
2006; Lappe et al., 2007; Pittas et al., 2007).
Both the deﬁnition of vitamin D deﬁciency and what
constitutes an appropriate supplementation strategy
continue to be debated (Malabanan et al., 1998;
Dawson-Hughes et al., 2005; Bischoﬀ-Ferrari et al.,
2006; Bischoﬀ-Ferrari & Dawson-Hughes, 2007; Han-
sen et al., 2008). While 1,25(OH)2Di st h ea c t i v ef o r m
of vitamin D, 25(OH)D is the appropriate index for
estimating whole-body vitamin D levels. This is the
result of both its substantially higher concentration
and the fact that even with a marked vitamin D
deﬁciency, elevated PTH levels will maintain the con-
version of 25(OH)D to 1,25(OH)2D, thereby sustain-
ing 1,25(OH)2D levels within normal ranges, despite
low reserves (Holick, 2004). It is generally accepted
that 25(OH)D levels of 20–30ng/mL (ng/mL  2.55
nmol/L) represent insuﬃciency, while levels below 20
and 10ng/mL represent deﬁciency and severe deﬁ-
ciency, respectively (Holick, 2007). Recent evidence
suggests that inter-laboratory variability in 25(OH)D
assessment may also complicate the interpretation of
vitamin D deﬁciency (Binkley et al., 2004).
Notwithstanding these issues, vitamin D deﬁciency
is increasingly being recognized as a worldwide
epidemic (Nowson & Margerison, 2002; Gordon
et al., 2004; Hashemipour et al., 2004; Andersen
et al., 2005; Rockell et al., 2005; Binkley et al.,
2007; Hannan et al., 2008). With the most common
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182cause of vitamin D deﬁciency being inadequate sun-
light exposure, it is not surprising that higher latitude
countries have a high incidence of deﬁciency (Ander-
sen et al., 2005). However, despite its high sunlight
hours, vitamin D deﬁciency is well recognized in
Middle Eastern women (Fonseca et al., 1984; Hatun
et al., 2005; Allali et al., 2006), and more recently in
inner city young adults in America (Gordon et al.,
2004), elite gymnasts in Australia (Lovell, 2008),
young Hawaiian skateboarders (Binkley et al.,
2007), and adolescent girls in England (Ward et al.,
2009). Vitamin D deﬁciency may have signiﬁcant
long-term health impacts (Holick, 2004; Giovannucci
et al., 2006), but it is also possible that a deﬁciency
will result in more immediate eﬀects on musculo-
skeletal health, with an increased risk of injuries such
as stress fractures (Ruohola et al., 2006; Lappe et al.,
2007, 2008). While there is no evidence to support or
refute the possibility that vitamin D deﬁciency will
aﬀect the injury proﬁle of tissues such as muscle, the
evidence presented herein suggests that further re-
search in this area is required. Furthermore, little is
known of any performance impact of vitamin D
deﬁciency; however, some authors suspect it may be
a marked impediment to performance when not
available in adequate levels (Cannell et al., 2009).
Indeed, in the early part of the 20th century, athletes
were allegedly using UVB rays as an ergogenic aid
(Hoberman, 1992; Cannell et al., 2009) and research
over that period suggested that both cardiovascular
ﬁtness and muscular endurance were enhanced with
exposure to ultraviolet radiation (Allen & Cureton,
1945). While vitamin D deﬁciency has long been
associated with muscle weakness (Floyd et al.,
1974; Irani, 1976; Russell, 1994; Ceglia, 2008), until
recently no speciﬁc etiological mechanism had been
described. Over the last 30 years, an independent
mechanism for vitamin D and muscle function has
slowly been unraveled. Subsequently, while limited,
there is evidence from a range of sources relating
vitamin D deﬁciency to suboptimal muscle function.
This review aims to describe the available evidence for
a role of vitamin D in muscle function, and thereby its
potential impact on the athletic individual.
Myopathy associated with vitamin D deﬁciency
Myopathy associated with vitamin D deﬁcient osteo-
malacia has been recognized for many years, pre-
senting predominantly as a proximal muscle
weakness or diﬃculty in walking upstairs (Floyd
et al., 1974; Irani, 1976; Russell, 1994; Ceglia,
2008). Traditionally, it was felt that this myopathic
presentation was secondary to osteomalacia and
disuse, rather than a direct eﬀect of vitamin D on
muscle; however, the increased mechanistic under-
standing of vitamin D challenges this presumption
(Glerup et al., 2000). As early as 1974, authors
had illustrated electromyographic changes in patients
with muscle weakness associated with osteomalacia
(Floyd et al., 1974), which improved with vitamin D
supplementation (Irani, 1976). Subsequently, numer-
ous reports attest to the reversibility of the myopathy
associated with vitamin D deﬁciency (Rimaniol
et al., 1994; Russell, 1994; Ziambaras & Dagogo-
Jack, 1997; Mingrone et al., 1999; Prabhala et al.,
2000).
Glerup et al. (2000) examined the impact of
vitamin D supplementation on vitamin D-associated
myopathy. In a preliminary study, a small group
(n58) of elderly men and women (mean age
63.1  5.3 years) with known osteomalacia had mus-
cle strength assessed using an isokinetic dynam-
ometer before and after 3 months of treatment with
alfacalcidol, ergocalciferol and calcium. They found
that over 3 months, muscle power increased signiﬁ-
cantly in all the muscle groups assessed, with a mean
improvement of 24.8  8.0%. Subsequently, they
compared a group of vitamin D-deﬁcient Arab
women with a control group of Danish women
with normal levels of vitamin D. At baseline, quad-
riceps maximum voluntary contraction (MVC), as
well as electrically stimulated twitch [single twitch,
maximum production rate (MPR) and maximal
relaxation rate (MRR)], were all signiﬁcantly lower
in the Arab women. Three months of vitamin D
supplementation, without strength training, in-
creased vitamin D levels and normalized PTH levels
in the Arab women, with a corresponding trend
toward normalization of the MVC, MPR and
MRR. Multivariate regression analysis revealed
that only 25(OH)D was signiﬁcantly associated
with MVC. Given that there was no correlation
between muscle power and markers of osteomalacia,
the authors concluded that normal levels of
25(OH)D are necessary for maintaining adequate
muscle function.
Morphology
Early biopsy studies (Floyd et al., 1974; Irani, 1976),
and subsequent case reports of the muscle weakness
associated with osteomalacia (Russell, 1994; Ziam-
baras & Dagogo-Jack, 1997), have revealed either
non-speciﬁc or type II muscle ﬁber atrophy. Sato et
al. (2005) were the ﬁrst to assess the impact of
vitamin D supplementation on muscle histopathol-
ogy. They biopsied the non-hemiplegic vastus later-
alis of 85 vitamin D-deﬁcient elderly stroke patients,
before and after a 2-year supplementation period
with either placebo or vitamin D2. At baseline they
found a normal range of type I ﬁbers, but a reduced
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the 2-year follow-up, the placebo group showed a
further reduction in type II muscle ﬁber diameter,
while in the vitamin D2-supplemented group the
relative content and mean diameter of type II ﬁbers
increased, with the ﬁber size correlating with
25(OH)D levels (Sato et al., 2005).
Age-related changes in muscle function
It is well recognized that muscle strength declines
with age, due to a number of contributory factors
(Iannuzzi-Sucich et al., 2002). However, the role of
vitamin D in any age-related strength decline con-
tinues to be debated (Janssen et al., 2002; Latham
et al., 2003a,b), with the majority of studies
being cross-sectional in design (Bischoﬀ et al., 1999;
Mowe et al., 1999; Bischoﬀ-Ferrari et al., 2004a,c;
Houston et al., 2007; Wicherts et al., 2007). These
studies appear to show a relationship between
25(OH)D levels and various measures of changes in
muscle strength and function with aging (Bischoﬀ
et al., 1999; Mowe et al., 1999; Bischoﬀ-Ferrari et al.,
2004a,c; Houston et al., 2007; Wicherts et al., 2007).
By contrast, a review of randomized-controlled
trials investigating vitamin D and/or calcium supple-
mentation concluded that while a combination of
calcium and vitamin D may improve physical func-
tion and reduce falls, there was no evidence that
vitamin D alone improved the strength or the phy-
sical function of elderly people (Latham et al.,
2003a,b). Increasingly, however, well-controlled
and designed studies support a role for vitamin D
in moderating the age-related decline in muscle
function (Bischoﬀ et al., 2003; Visser et al., 2003;
Gerdhem et al., 2005), with a potential mechanism
described recently (Bischoﬀ-Ferrari et al., 2004a,c;
Roth et al., 2004).
For example, Visser et al. (2003) prospectively
investigated the impact of low 25(OH)D and high
serum PTH in 1008 men and women aged over 65
years (mean 74 years) and found that individuals
with a lower 25(OH)D and/or higher PTH levels
were signiﬁcantly more likely to lose grip strength
and muscle mass. They also found 25(OH)D levels of
30ng/mL to be a threshold for optimal muscle
function. In the same year, Bischoﬀ et al (2003)
performed a 12-week double-blind, randomized-
controlled trial utilizing vitamin D and calcium vs
calcium supplementation alone. They reported a
signiﬁcant improvement in knee ﬂexor and extensor
strength, grip strength and functional (timed up
and go) testing, in their elderly group following
vitamin D and calcium, vs calcium supplementation
alone. Further, Gerdhem et al. (2005), in a 3-year
study of 986 Swedish 75-year-old women, found
that reduced 25(OH)D levels correlated with reduced
gait speed, reduced knee ﬂexor and extensor strength
and increased risk of falls. Similarly, Broe et al.
(2007), in a 5-month prospective randomized-
controlled trial, illustrated a dose-dependent
(800IU/day) impact of vitamin D supplementation
on signiﬁcantly reducing falls in the elderly. Several
other prospective studies have reported similar func-
tional beneﬁts (Verhaar et al., 2000; Dhesi et al.,
2004; Sato et al., 2005; Bunout et al., 2006) and a
meta-analysis of studies has conﬁrmed the beneﬁt
of vitamin D supplementation on fall prevention
(Bischoﬀ-Ferrari et al., 2004b).
By contrast, in a large prospective randomized-
controlled trial, Latham et al. (2003a,b) assessed the
relative beneﬁts of home resistance exercise or a
single high dose of vitamin D, on self-reported
physical health, risk of falls and functional perfor-
mance at 3 and 6 months. Despite increasing the
serum 25(OH)D level in those individuals treated,
they found no signiﬁcant impact of 25(OH)D on any
of the functional outcome parameters (Latham et al.,
2003a,b).
In an eﬀort to evaluate a potential mechanism of
vitamin D-associated changes in muscle morphology
and function with age, the expression of the vitamin
D Receptor (VDR) was assessed in the gluteus
medius and transversospinalis muscles of female
patients undergoing hip arthroplasty and spinal
operations, respectively (Bischoﬀ-Ferrari et al.,
2004a,c). The authors found that VDR expression
decreased with age and that VDR expression was
unaﬀected by either 25(OH)D or 1,25(OH)2D levels.
The authors suggested that age-related decline in
muscle strength may be related to reduced VDR
expression. Furthermore, VDR polymorphisms
may also result in variable susceptibility to age-
related sarcopenia (Roth et al., 2004).
By far the majority of vitamin D studies have been
performed on the elderly population, who are prone
to sarcopenia, and as a result there is limited evidence
for the impact of vitamin D on healthy young
individuals. However, El-Hajj et al. (2006) reported
a 1-year prospective double-blind, placebo-con-
trolled trial of low- and high-dose vitamin D3 in
179 adolescent Lebanese girls. In vitamin D-supple-
mented individuals they found increased lean mass,
bone area and bone mass, particularly in pre-menar-
chal girls, but found no increase in grip strength.
Furthermore, there were no signiﬁcant ﬁndings
regarding 25(OH)D and muscle mass or grip strength
in a similar cohort of male adolescents (El-Hajj
et al., 2006). By contrast, a recent study of 99 post-
menarchal adolescent girls in England found a
positive relationship between serum 25(OH)D level
and jump height, jump velocity and power (Ward
et al., 2009).
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The VDR
Attempts to identify an independent role for vitamin
D on skeletal muscle began in earnest in 1975 when
25(OH)D, presumably via a speciﬁc receptor, was
proposed to directly stimulate the synthesis of pro-
tein, ATP and inorganic phosphate in the rat dia-
phragm muscle (Birge & Haddad, 1975). However,
there continued to be some debate as to whether or
not vitamin D has a truly independent eﬀect on
muscle. Wassner et al. (1983) discredited the afore-
mentioned study, and concluded that vitamin D has
no direct eﬀect on muscle, rather its impact was felt
to be indirect, via calcium and insulin (Wassner et al.,
1983). This debate was settled in 1985 when a VDR
was recognized within cultured rat myoblast cells,
thereby showing that muscle is a direct target organ
for 1,25(OH)2D (Simpson et al., 1985). The VDR has
subsequently been described in tissues such as
smooth muscle, heart muscle, liver, lung, colon,
gonads and skin (Pfeifer et al., 2002; Nibbelink et
al., 2007), and was recently isolated from human
skeletal muscle (Bischoﬀ et al., 2001; Bischoﬀ-Ferrari
et al., 2004a,c).
1,25(OH)2D receptors have been characterized as
members of the steroid hormone super-family, acting
as a hormone-inducible transcription factor (Peng
et al., 2004; Liao et al., 2008). Furthermore, VDR
have been shown to have various genetic polymorph-
isms, which may aﬀect their function within skeletal
muscle (Geusens et al., 1997; Grundberg et al., 2004;
Hopkinson et al., 2008). In combination with co-
factors ‘‘retinoid  receptor’’ and ‘‘Steroid Receptor
Coactivator 3’’ (SRC), the VDR: 1,25(OH)2D com-
plex modulates gene expression of a number of
proteins, via binding to speciﬁc target gene promoter
regions, known as ‘‘vitamin D response elements’’
(VDRE) (Peng et al., 2004; Liao et al., 2008). This
may include both proteins with roles in calcium
metabolism such as calbindin (Fleet, 2004), but also
proteins not directly related to calcium metabolism
such as insulin-like growth factor binding protein 3
(IGFBP-3) (Peng et al., 2004).
To assess the role of the VDR in the skeletal
muscle of mice, a generation of VDR gene-deleted
mice and myoblast cell lines were examined (Endo
et al., 2003). In order to exclude the impact of
secondary metabolic abnormalities such as hypocal-
cemia, gene-deplete mice were assessed at 3 weeks,
before weaning and development of secondary meta-
bolic problems. Analysis revealed that VDR null
mice had ﬁber sizes in the quadriceps and other
muscle groups 20% smaller than VDR-replete mice
and that this trend progressed as secondary meta-
bolic factors developed from 3 weeks of age. Further-
more, VDR null mice exhibited increased expression
of myogenic transcription factors myf5, E2A and
myogenin compared with normal mice along with
inappropriate expression of embryonic and neonatal
type myosin heavy chain (Endo et al., 2003). These
ﬁndings support a direct role for 1,25(OH)2D and the
VDR in both the metabolic processes and the tran-
scriptional regulation of skeletal muscle. Subse-
quently, it is likely that 1,25(OH)2D and the VDR
inﬂuence skeletal muscle via both genomic and non-
genomic mechanisms (Schmidt et al., 2000; Nguyen
et al., 2004).
Genomic actions of vitamin D
Typical of steroid hormones, the binding of
1,25(OH)2D to the VDR results in enhanced tran-
scription of a range of proteins, including those
involved in calcium metabolism (Fleet, 2004). Cal-
cium is a critical modulator of skeletal muscle func-
tion and any perturbation to calcium handling may
impact on both its contractile and relaxation proper-
ties (Berchtold et al., 2000). Therefore, 1,25(OH)2D
may aﬀect muscle function through both calcium-
related protein transcription and total body calcium
levels. Recently, however, it has transpired that
1,25(OH)2D also has a transcription-enhancing role
on proteins other than those involved directly in
calcium metabolism. One such protein, relevant to
the discussion of skeletal muscle, is IGFBP-3. In
order to illustrate the potential impact of
1,25(OH)2D on skeletal muscle function, the role of
insulin-like growth factor-1 (IGF-1) and IGFBP-3
will be described in further detail.
IGF-1 is a 7.5kDa polypeptide, structurally simi-
lar to insulin (Thissen et al., 1994). It induces pro-
liferation, diﬀerentiation and hypertrophy of skeletal
muscle (Barton-Davis et al., 1998) and is a key
component in muscle regeneration (Schertzer et al.,
2007). IGF-1 has at least three isoforms resulting
from splice variations, namely IGF-1Ea, IGF-1Eb
and IGF-1Ec (Goldspink, 2005). IGF-1Ea is the
circulating form of IGF-1 expressed from the liver,
whereas IGF-1Ec, also known as mechano-growth
factor (MGF), is the tissue isoform released from
skeletal muscle cells, believed to exert exclusively
autocrine/paracrine actions (Goldspink, 1999).
Each isoform may have slightly diﬀerent biological
actions, with IGF-1Ea stimulating terminal diﬀeren-
tiation of muscle cells into myotubes and promoting
stem-cell mediated muscle regeneration. By contrast,
MGF responds to tissue damage, controls local
tissue repair and is more potent than IGF-1Ea at
causing hypertrophy (Goldspink, 1999). Subse-
quently, IGF-1 is recognized as both a potential
means for addressing age-related sarcopenia
(Grounds, 2002) and as an illegal ergogenic aid in
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99% bound to a carrier protein IGFBP-3. Only 1%
of serum IGF-1 is ‘‘free’’ (fIGF-1) to exert the
biological eﬀects, and when unbound, IGF-1 is
rapidly cleared (Liao et al., 2008).
IGFBP-3 is a member of the IGFBP family, which
bind IGF-1 in the serum, the extracellular matrix or
on cell surfaces (Berg et al., 2007) with high aﬃnity
and speciﬁcity (Baxter, 2000; Peng et al., 2004). The
binding of IGF-1 to IGFBP’s may have both inhibi-
tory and stimulatory eﬀects on IGF-1 function
(Baxter, 2000). The IGF-1–IGFBP-3 complex may
block the binding of IGF-1 to its receptors, thereby
mitigating its eﬀect on DNA synthesis, growth and
glucose regulation (Baxter, 2000), but preventing its
otherwise rapid clearance (Liao et al., 2008). Further-
more, presumably as a result of increased free IGF-1,
the inhibition of IGF-1 binding to IGF-1BP has been
shown to enhance the healing of mice skeletal muscle
(Schertzer et al., 2007). It has also been suggested
that IGFBP may have a role independent of any
IGF-1 binding, inhibiting both DNA synthesis and
inducing apoptosis (Baxter, 2000; Peng et al., 2004).
IGFBP-3 expression is regulated by a number of
factors, including 1,25(OH)2D (Peng et al., 2004),
with a VDRE in the promoter region for human
IGFBP-3 recently identiﬁed (Peng et al., 2004). Thus,
1,25(OH)2D, in combination with the VDR and
other elements, such as SRC-3 (Liao et al., 2008),
can positively inﬂuence IGFBP-3 expression (Fig. 1).
For example, without SRC-3 cofactor combination
with the activated VDR, transcriptional expression
of IGFBP-3 is reduced, and as a result IGF-1
clearance is increased (Liao et al., 2008).
The potential signiﬁcance of this process involving
IGF-1 was illustrated in a recent investigation of
children with vitamin D-deﬁcient rickets, before and
after supplementation with vitamin D (Soliman et
al., 2008). The authors found that the growth rates
and height of the children increased with vitamin D
supplementation, and that there was a signiﬁcant
correlation between serum concentrations of IGF-1
and the percentage increment in 25(OH)D concen-
trations, with IGF-1 concentrations increasing sig-
niﬁcantly after treatment with vitamin D. Both the
length and the growth rate correlated with the IGF-1
concentration, leading the authors to conclude that
the growth spurt observed in children with rickets
after vitamin D supplementation is mediated via
through an increase in IGF-1 (Soliman et al., 2008).
VDR polymorphisms and skeletal muscle function
The VDR gene located on chromosome 12
(12q13.11) (Bray et al., 2009) is known to have
various genetic polymorphisms including Bsm1,
Fok1, Apal and Taq1, which have been associated
with various functional outcomes (Geusens et al.,
1997; Roth et al., 2004; Hopkinson et al., 2008). The
Fok1 polymorphism involves a T to C transition in
exon 2 of the VDR gene, resulting in a shorter (424)
amino acid VDR than the T allele (427) (Guo et al.,
2006), and has been associated with variations in
both bone mineral density (Zhang et al., 2008) and
diﬀerential responses of bone density to strength
training (Tajima et al., 2000; Rabon-Stith et al.,
2005). Furthermore, an association with fat-free
mass and risk of age-related sacropenia has been
described (Roth et al., 2004) and in patients suﬀering
from chronic obstructive pulmonary disease (COPD),
Fok1 C homozygotes (also known as FF) were found
to have signiﬁcantly weaker quadriceps than either
CT heterozygotes or T (ﬀ) homozygotes (Hopkinson
et al., 2008).
Geusens et al. (1997) assessed the impact of VDR
polymorphis ms on grip and quadriceps strength.
Five hundred and one healthy women over the age of
70 were assessed for quadriceps and grip strength and
the VDR genotype Bsm1 (a single nucleotide poly-
morphism found in intron 8 (Guo et al., 2006)). In
this cross-sectional study, the bb genotype (that is the
presence of the restriction site on both alleles) was
found to be signiﬁcantly stronger than BB or hetero-
zygote genotype. This ﬁnding was supported by a
study involving patients with COPD, whereby the bb
polymorphism was associated with stronger quad-
riceps muscles (Hopkinson et al., 2008). However,
not all studies have shown similar results. Grundberg
et al. (2004) examined the relationship between Bsm1
polymorphisms and muscle strength utilizing 170
pre-menopausal Swedish women. Women homozy-
gous for Bsm1 BB or poly-A repeat ss were found to
have higher hamstring strength than the bb or LL
genotypes. Furthermore, no signiﬁcant associations
were found between VDR polymorphisms and either
grip strength or quadriceps strength. Similarly,
Roth et al. (2004) found no impact of the Bsm1
Fig. 1. Potential role for 1,25-OH vitamin D in non-cal-
cium-related, genomic action in muscle cells.
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elderly men.
Non-genomic effects of vitamin D on muscle
A pathway of vitamin D action, independent of the
intra-nuclear transcription process, was mooted in
the 1980s and has been characterized more recently
(Boland et al., 1995; Nguyen et al., 2004).
1,25(OH)2D has been shown to be involved in the
rapid regulation of membrane calcium channels in
cultured chick skeletal muscle cells (Vazquez et al.,
1997). Subsequently, a membrane receptor in rat
chondrocytes with a higher molecular weight than
the intra-nuclear VDR (known as the membrane-
associated rapid response steroid-binding protein
(MARRS) (Fleet, 2004)), speciﬁc for 1,25(OH)2D,
has been identiﬁed (Nemere et al., 1998). Recent
evidence illustrating that the application of
1,25(OH)2D results in the translocation of the
VDR to the plasma membrane in chick skeletal
muscle cells (Capiati et al., 2002) and that the rapid
eﬀects of vitamin D require the VDR (Nguyen et al.,
2004) suggests that a combination of both the intra-
nuclear VDR and other membrane receptors (i.e.,
MARRS) may be involved in the rapid actions of
vitamin D (Capiati et al., 2002). While the exact
mechanism of the non-genomic action of vitamin D
remains a controversial and heavily researched topic,
it is widely accepted that vitamin D levels have a
rapid eﬀect on the membrane calcium channels of
muscle cells in numerous species (Schmidt et al.,
2000; Fleet, 2004; Nguyen et al., 2004). As calcium
is a critical modulator of skeletal muscle function
(Berchtold et al., 2000), it follows that vitamin D
levels may have a signiﬁcant impact on muscle
function, performance and injury risk.
Conclusion
Vitamin D deﬁciency has traditionally been consid-
ered the domain of the elderly; however, this is
changing as evidence of high rates of vitamin D
deﬁciency is recognized in today’s youth. Vitamin
D deﬁciency is now endemic in many communities
and athletes are not spared this condition. Increas-
ingly, vitamin D deﬁciency is recognized as being
associated with both chronic health conditions and
musculo-skeletal injuries such as stress fractures;
however, its potential impact on other tissues such
as muscle is not well described.
The identiﬁcation of the VDR, its various poly-
morphisms, and variable expression with aging, has
provided some insight into the complex mechanisms
by which vitamin D and its metabolic pathways may
aﬀect muscle function. The recognition of both
genomic and non-genomic eﬀects of vitamin D in
skeletal muscle, with the resultant impact on both
calcium metabolism and protein transcription,
further illustrates the signiﬁcance of vitamin D in
muscle function. Further clariﬁcation of the complex
role of the VDR in both muscle and other musculo-
skeletal tissues is required.
Despite the limited evidence available at the time,
athletes and trainers in the early 20th century be-
lieved that UVB radiation was beneﬁcial to athletic
performance. Accumulating evidence supports the
existence of a functional role for vitamin D in
skeletal muscle with potentially signiﬁcant impacts
on both the performance and injury proﬁles of
young, otherwise healthy athletes. While further
research is required to evaluate the level of vitamin
D required for optimal muscular function, clinicians
working with athletes should be aware of the broad
impact of vitamin D deﬁciency on the athlete.
Vitamin D should no longer be considered only to
have an impact on calcium metabolism and bone
morphology, but should be recognized to have a
broad impact on the organism as a whole. Further
epidemiological and in vitro research into the poten-
tial impact of vitamin D deﬁciency on muscle func-
tion, morphology and performance in young athletic
individuals is required.
Key words: IGF-1, injury, deﬁciency.
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